PA
IMCR icon

Parallel Advisors’s Immunocore IMCR Stock Holding History

Parallel Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-917
Closed -$27.6K – 4006
2026
Q1 		$27.6K Buy
917
+38
+4% +$1.23K ﹤0.01% 2321
2025
Q4 		$30.5K Sell
879
-36
-4% -$1.27K ﹤0.01% 2099
2025
Q3 		$33.2K Sell
915
-91
-9% -$3.09K ﹤0.01% 2004
2025
Q2 		$31.6K Hold
1,006
– – ﹤0.01% 1971
2025
Q1 		$29.8K Hold
1,006
– – ﹤0.01% 1929
2024
Q4 		$29.7K Buy
1,006
+9
+0.9% +$285 ﹤0.01% 1946
2024
Q3 		$31K Hold
997
– – ﹤0.01% 1849
2024
Q2 		$33.8K Hold
997
– – ﹤0.01% 1727
2024
Q1 		$64.8K Buy
997
+47
+5% +$3.23K ﹤0.01% 1377
2023
Q4 		$64.9K Hold
950
– – ﹤0.01% 1309
2023
Q3 		$49.3K Buy
950
+185
+24% +$10.9K ﹤0.01% 1402
2023
Q2 		$45.9K Buy
765
+758
+10,829% +$43.3K ﹤0.01% 1435
2023
Q1 		$346 Sell
7
-31
-82% -$1.74K ﹤0.01% 3213
2022
Q4 		$2.17K Buy
38
+11
+41% +$619 ﹤0.01% 2651
2022
Q3 		$1K Buy
+27
New +$1.29K ﹤0.01% 2933

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Parallel Advisors's IMCR Position: Q2 2026 in Review

Parallel Advisors sold out of Immunocore (IMCR) in Q2 2026, closing a stake of 917 shares — an estimated $27.6K sold.

Parallel Advisors first reported a position in IMCR in Q3 2022 and held it in 15 quarters. The position peaked at $64.9K in Q4 2023. 135 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Parallel Advisors reported no remaining Immunocore position as of Q2 2026 after selling out during the quarter.
  • Parallel Advisors sold 917 Immunocore shares in Q2 2026, an estimated $27.6K.
  • Parallel Advisors first reported a position in Immunocore in Q3 2022 and held it in 15 quarters.
  • Parallel Advisors's Immunocore position peaked at $64.9K in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.